Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?

The EV-302 study 1 Powles T. Valderrama B.P. Gupta S. Bedke J. Kikuchi E. Hoffman-Censits J. Iyer G. Vulsteke C. Park S.H. Shin S.J. et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N. Engl. J. Med. 2024; 390: 875-888https://doi.org/10.1056/NEJMoa2312117 Crossref PubMed Scopus (32) Google Scholar marks a pivotal leap in the management of advanced urothelial carcinoma, setting a new benchmark for frontline therapy. Enfortumab vedotin plus pembrolizumab is the first combination therapy that has ever outperformed standard chemotherapy. The degree of benefit and the reported safety profile should make this combination a first-choice option for most patients with advanced-stage urothelial carcinoma. The EV-302 study 1 Powles T. Valderrama B.P. Gupta S. Bedke J. Kikuchi E. Hoffman-Censits J. Iyer G. Vulsteke C. Park S.H. Shin S.J. et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N. Engl. J. Med. 2024; 390: 875-888https://doi.org/10.1056/NEJMoa2312117 Crossref PubMed Scopus (32) Google Scholar marks a pivotal leap in the management of advanced urothelial carcinoma, setting a new benchmark for frontline therapy. Enfortumab vedotin plus pembrolizumab is the first combination therapy that has ever outperformed standard chemotherapy. The degree of benefit and the reported safety profile should make this combination a first-choice option for most patients with advanced-stage urothelial carcinoma.